Dr. Che Fengsheng, Chairman and Executive Director of Sihuan Pharmaceutical said, "As bacteria are becoming increasingly resistant to existing antibacterial drugs, super bacteria have posed the most serious threat to human health. The World Health Organization (WHO) has predicted that 10 million people will die as a result of super bacterial infections each year by 2050. EvaluatePharma, a pharmaceutical market research agency, has predicted that the annual sales of plazomicin will reach US$313 million in 2022. The Group expects that plazomicin will generate significant economic benefits after its launch in the Greater China Region. In addition, the selection of azithromycin capsule in the second batch of the National Centralized Medicine Procurement will help the Group to quickly enter the PRC domestic sales market of azithromycin capsule, increase market presence and further accelerate its development in the field of anti-infective drugs."
